FIGURE 4.

The different donor-derived cell-free DNA (dd-cfDNA) levels (y-axis) across distinct clinical events (x-axis) for 19 unique patients with multiple associated plasma samples. Clinical events included: healthy stable, acute cellular rejection (ACR), antibody-mediated rejection (AMR), chronic lung allograft dysfunction (CLAD), allograft infection in absence of concurrent rejection (INFXN) and follow-up (F/U) testing 1–2 months after treatment. Individual patient dd-cfDNA levels demonstrated a trend for higher levels in association with AMR and CLAD clinical events.